Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Kuan-Li Wu

18PUBLICATIONS

21CO-AUTHORS

Cancer diagnosisMolecular targetsAir pollution modelling and controlPredictive and prognostic markersCancer cell biology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (18)

Sort by Publication Date:

|Sep 19, 2024

A rare case of tracheal squamous cell carcinoma presented with critical airway obstruction.

Chen-Yu Ho, Yu-Wei Liu, Wei-An Lai

|Mar 25, 2024

Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.

Chia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung

|Apr 13, 2023

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with <i>EGFR</i>-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib.

Ming-Ju Tsai, Jen-Yu Hung, Juei-Yang Ma

|Jan 08, 2023

Ladinin 1 Shortens Survival via Promoting Proliferation and Enhancing Invasiveness in Lung Adenocarcinoma.

Chao-Yuan Chang, Yung-Chi Huang, Hung-Hsing Chiang

|Jan 08, 2023

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes.

Chia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung

|Jan 08, 2023

Single-Cell Transcriptomic Profiles of Lung Pre-Metastatic Niche Reveal Neutrophil and Lymphatic Endothelial Cell Roles in Breast Cancer.

Yung-Chi Huang, Chao-Yuan Chang, Yu-Yuan Wu

Pageof 3

Frequent Collaborators

11 joint publications

Jen-Yu Hung

6 joint publications

Cheng-Hao Chuang

6 joint publications

Chih-Jen Yang

5 joint publications

Inn-Wen Chong

5 joint publications

Ming-Ju Tsai

3 joint publications

Yu-Wei Liu

3 joint publications

Hsiao-Chen Lee

3 joint publications

Hsiu-Mei Chang

2 joint publications

Yu-Kang Tu

2 joint publications

Wei-An Chang

Frequent Collaborators

11 joint publications

Jen-Yu Hung

6 joint publications

Cheng-Hao Chuang

6 joint publications

Chih-Jen Yang

5 joint publications

Inn-Wen Chong

Top Related Videos

Endotracheal Intubation via Tracheotomy and Subsequent Thoracotomy in Rats for Non-Survival Applications

Endotracheal Intubation via Tracheotomy and Subsequent Thoracotomy in Rats for Non-Survival Applications

Published on : Mar 15, 2024

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Endotracheal Intubation via Tracheotomy and Subsequent Thoracotomy in Rats for Non-Survival Applications

Endotracheal Intubation via Tracheotomy and Subsequent Thoracotomy in Rats for Non-Survival Applications

Published on : Mar 15, 2024

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos